Mitwalli A, Wakeel J Alam A Tarif N Abu-Afsha A
This option is best if youre comfortable reviewing and finalizing the appeal yourself
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study
No nickel-and-dime add-ons that inflate the real cost
This review will systematically discuss the recent advances of the stapled peptides with various forms of constraints as therapeutic candidates with respect to the design principles, structural stability, bioactivity, cell permeability, and potential applications in therapeutics